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tration and monitoring were estimated by an expert panel survey
conducted among 10 rheumatologists. Both health beneﬁts and
future costs were discounted at annual rate of 3%. One-way
sensitivity analyses were performed on key model parameters by
varying the input values by 10%. RESULTS: Compared to
current treatment arm, adding RTX yielded an incremental cost-
effectiveness ratio (ICER) of USD$18,152 (NTD$589,945) per
QALY gained. RTX remained cost-effective under one-way sen-
sitivity testing. Furthermore, applying RTX right after ETAN
or ADAL inadequate response (IR) rather than switching
between these two TNF inhibitors resulted in signiﬁcant cost-
savings of USD$14,922 (NTD$484,994) and USD$19,707
(NTD$640,481) respectively. CONCLUSION: From Taiwan
BNHI perspective, this demonstrates that adding RTX to current
treatment options for RA patients who respond inadequately to
TNF inhibitor therapy is cost-effective, in addition, applying
RTX right after one TNF inhibitor (ETAN or ADAL) IR is
cost-saving.
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OBJECTIVE: To assess cost-effectiveness of zoledronic acid
compared to risedronate in the Brazilian private health care
system, by health plan companies’ perspective. METHODS:
Decision analytic model (Markov) to estimate the incremental
cost effectiveness ratio of zoledronic acid compared to risedr-
onate for the treatment of osteoporosis in Brazil in 2007. The
target population was a hypothetic cohort of women with
osteoporosis aged 65 years in a time horizon of 5 years. The
epidemiological data related to osteoporosis and drug’s efﬁcacy
were obtained from critical appraisal of scientiﬁc literature. The
costs were collected from electronic claims databases of
patients enrolled in Brazilian health plans. The outcome ana-
lyzed was the cost per osteoporotic hip fracture avoided. Costs
and clinical beneﬁts related to the treatment were discounted at
a rate of 3%. RESULTS: In the base case scenario, zoledronic
acid reduced the incidence of fractures in comparison to risedr-
onate (0.33 fractures against 0.46 fractures), with similar
annual costs of osteoporosis treatment and its complications in
both arms of the model (US$10,607.35 against US$10,606.22,
incremental costs of US$1.13). CONCLUSION: The study
demonstrated that the use of zoledronic acid compared to
risedronate could prevent more hip fractures, with similar costs
in the brazilian private health system. This study highlights the
savings to health plan companies if an osteoporotic hip fracture
can be avoided.
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OBJECTIVE: To consolidate the cost-effectiveness (CE) data of
biologics in Rheumathoid Arthritis (RA) and explore their local
applicability. METHODS: Systematic review of CE studies (e.g.,
electronic databases searched to Nov. 2007) comparing biologics
with conventional DMARDs for RA patients. Details regarding
study characteristicswere abstracted using a framework byDrum-
mond et al. 2005 and study quality via Neuman et al. 2000 (score
1–7 higher better). ICER data was extracted, purchasing-power-
parity converted and pro-rated to 2006 Canadian $. RESULTS:
Nineteen CUA and 2 CEA studies published in 2002–2007
(UK = 7 studies, US 5, Canada = 3, Sweden = 4, Netherlands/
Japan = 1 each; ETA = 10, INF = 8, ADA = 2, ANA = 1; payer
perspective = 11, societal = 7 and not reported = 3 were identiﬁed
via screening 337 citations and reviewing 50 full-text articles.
Study methods varied (e.g., input efﬁcacy data, time horizon,
offset costs) but reporting quality was high (17/21). 20/21 study
populations involved RA patients refractory to one or more
DMARDs. The direct cost per QALY was $127–174 K for ETA
third line in Canada (n = 2 studies), $60–104 K mid-sequence in
the UK (n = 2), $60–176 K in Sweden (n = 3), and $256–483 K in
The Netherlands (n = 1). For INF with methotrexate, the cost per
QALY was $99–114 K in Canada (n = 1) and $62–289 K in the
UK (n = 2). It was $62–293 K for ADA (n = 1) and $233–1290 K
for ANA (n = 1). Other results from industry-funded studies
varied (n = 7). Antibodies against TNF was showed to be cost
effective at $50 K per QALY using data from the UK Rheumatol-
ogy Biologics Registry (n = 1). Two sources of uncertainty
frequently identiﬁed in sensitivity analyses: long-term disease
progression (10/17) and associated QALY (7/17). CONCLU-
SION: For direct cost, the relative cost effectiveness of the biolog-
ics is consistent with their relative clinical effectiveness, especially
the estimates of HAQ progression while on treatment.
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OBJECTIVE: To investigate the cost-effectiveness of biological
response modiﬁers in patients with moderate to severe rheuma-
toid arthritis who have experienced an inadequate response to
methotrexate METHODS: A decision analytic model was con-
structed to estimate the costs and effectiveness of adalimumab,
anakinra, etanercept, and inﬂiximab alone or in combination
with methotrexate for 6 months. Effectiveness was measured by
American College of Rheumatology response criteria (ACR20) as
reported in published clinical trials. Costs included direct medical
costs (including medication, monitoring, and adverse event costs)
and indirect costs due to impaired work productivity. Extensive
univariate and probabilistic sensitivity analyses were performed.
RESULTS: In the base case, costs for 6 months of therapy were
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lowest for etanercept monotherapy ($22,487) and highest with
the combination of inﬂiximab and methotrexate ($24,807). For
monotherapy and combination therapy regimens, etanercept was
the least expensive option and most effective option compared to
other treatments, although differences in cost and effectiveness
across treatments were relatively small. After eliminating domi-
nated options, etanercept +MTX therapy increased the probabil-
ity of achieving an ACR 20 by 7% points and increased total
costs by $199 over etanercept monotherapy agent, resulting in an
incremental cost-effectiveness ratio of $2843 per additional
response. The incremental cost-effectiveness of combination
therapy compared to monotherapy was not markedly altered in
sensitivity analyses. CONCLUSION: Findings from this study
suggest that there are relatively small differences in cost and
effectiveness across biological response modiﬁers. Combination
therapy with biological response modiﬁers appears to provide an
increase in response compared to methotrexate alone, but at a
cost. Whether combination therapy can be considered cost-
effective depends on the value attached to achieving ACR
response.
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OBJECTIVE: Evaluate the cost-effectiveness of inﬂiximab com-
pared to adalimumab in early arthritis from an institutional
perspective. METHODS: To compare the cost and effectiveness,
a decision tree model was structured with a temporary horizon of
54 weeks. Only costs per drug were considered for this analysis,
as the rest of the costs are similar for institutional buyers.
Comparators: 3 mg/kg i.v. inﬂiximab + 15 mg oral metotrexate
(MTX) weekly. Inﬂiximab is administered at weeks 0, 2 and 6,
and every 8 weeks thereafter. Adalimumab subcutaneous injec-
tions of 40 mg every two weeks + 15 mg weekly of metotrexate
(oral). The effectiveness measures considered were the percentage
of patients achieving the ACR 50 and 70 response levels and
were obtained from international literature. Percentage of
patients achieving the ACR 50 and 70 levels with each treatment:
78% and 67% for inﬂiximab + metotrexate and 62% and 49%
respectively for the combination of adalimumab plus metotrex-
ate. Costs were estimated using prices of 2007 and are expressed
in United States dollars (exchange rate of 10.93 pesos/1 USD).
RESULTS: The expected annual treatment cost is $15,720.80
for inﬂiximab and $15,896.20 for adalimumab. The
cost-effectiveness ratios for ACR 50 and 70 per drug type are:
$20,154.80 and $23,463.90 respectively for inﬂiximab; and
$25,639 and $32,441.20 respectively for adalimumab. The
incremental cost-effectiveness ratio for inﬂiximab vs. adali-
mumab is -$1096.20 for ACR 50 and $974.40 for ACR 70. The
sensitivity analysis showed that these results are sensitive to drug
price variations. CONCLUSION: Inﬂiximab is a cost-effective
alternative compared to adalimumab for the treatment of early
arthritis from an institutional perspective in Mexico.
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OBJECTIVE: To evaluate from a Mexican public health
care institution perspective, the efﬁciency for using monthly
ibandronate for prevention of osteoporotic hip fractures in
Mexican women aged ﬁfty and older. METHODS: A hypotheti-
cal intervention to compare ibandrontate monthly versus alen-
dronate weekly to prevent osteoporotic hip fractures in
Mexican ﬁfty years and older women was modeled. The model
considers both efﬁcacy reported to each drug and the effective-
ness for their massive use based on the adherence to the therapy
reported. Taking into account both groups of women, those that
completed treatment and those that abandoned it, the model
estimates the total number of hip fractures possibly avoided for
each alternative and the investment required, only in terms of
direct cost. Considering that in Mexico there is not a deﬁned
cost-effectiveness threshold, the attention cost for hip fracture
was proposed like this. RESULTS: The attention cost for a hip
fracture in Mexico is reported at approximately USD$5100.
Although the model estimated a higher total direct cost for
using ibandronate (due to it’s higher rate of adherence) the
estimated ICER was USD$4734; this means the cost for addi-
tional hip fracture avoided comparing to alendronate. CON-
CLUSION: The use of monthly ibandronate to treat
osteoporosis and prevent osteoporotic hip fractures is a cost-
effective alternative. Although the public health care institutions
could be spending a maximum amount near to actual cost for
hip attention, it is possible to obtain additional savings if the
indirect costs of hip fractures and their associated deaths are
considered.
PMS17
LONGITUDINAL ESTIMATES AND COST-EFFECTIVENESS
ANALYSIS OF ANTI-RESORPTIVE AGENTS FOR
GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND
FRACTURES BASED ON US NATIONAL SURVEYS
Yeh JY1, Lawson K2, Novak S3, Rascati KL2, Barner JC2, Johnsrud M2
1Cleveland Clinic, Cleveland, OH, USA, 2The University of Texas at
Austin, Austin,TX, USA, 3The JeSTARx Group, Austin,TX, USA
OBJECTIVE: Long-term glucocorticoid use may lead to
glucocorticoid-induced osteoporosis and fractures which require
proper management. This study aims to aid decision-making on
preventive use of anti-resorptive agents for female long-term oral
glucocorticoid tablet users. METHODS: A retrospective analysis
of 1996–2004 Medical Expenditure Panel Survey data was con-
ducted to evaluate “actual use” outcomes. Direct medical costs
(in 2006 dollars) including selected adverse events related to
anti-resorptive agents were evaluated. Logistic analysis was per-
formed to estimate odds ratios of new fractures and osteoporosis
in treatment groups compared to the control group. Markov
modeling with second-order Monte Carlo simulations was
used to yield long-term estimates of these outcomes and address
parameter uncertainty. RESULTS: Of 1692 qualiﬁed female long-
term glucocorticoid users (representing 2.65% of the female
non-institutionalized U.S. population; average age = 49.8 years;
average prednisone-equivalent dose = 10.7 mg/day; average
therapy length = 215 days; white = 85.6%), 29.9% reported use
of any anti-resorptive agent; of those, 76.5% used hormone
replacement therapy (HRT) only, 12.1% used bisphosphonates
only, 2% used calcitonin only, 1.6% used raloxifene only and
7.8% used more than one anti-resorptive agent. Compared to
the controls, the estimated 10-year/lifetime incremental cost-
effectiveness ratios (ICERs; cost per fracture avoided) are $2,250/
$7,776 for HRT, $10,149/$28,078 for bisphosphonates,
$27,891/$46,102 for raloxifene and $60,862/$61,660 for calci-
tonin in hypothetical 50-year-old female glucocorticoid users. By
using the cost-effectiveness acceptability curve, different decision
makers may ﬁnd the corresponding range of probabilities that
remain cost-effective based on personalized willingness-to-pay.
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